AI’s impact on the future of pharma and drug discovery

The recent surge in activity in deploying AI capabilities in pharmaceutical R&D shows no sign of abating, with ‘big pharma’ investing significant capital in streamlining or accelerating the drug discovery process and applying AI methods to identifying new targets and medicines. If AI delivers on its promise, then there will be a material increase in the rate of new medicines coming to market. This could lead to a corresponding up-tick in the demands on manufacturing. Running in parallel is the question of how the same technologies can be applied to increase efficiency and improve outcomes in manufacturing as well as how AI technology might help improve efficiencies within these businesses. 

AI meets ‘big pharma’

Major pharmaceutical companies are data-rich and expert at developing new medicines starting from an implicated gene, protein, process or pathogen. They have powerful computational tools at their disposal and are early adopters of new technology. The leading AI companies have developed tools capable of analysing vast data sets, including natural language documents. The convergence of the two means that the deployment of leading-edge AI to pharmaceutical R&D is accelerating.

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
Poolbeg Pharma

More articles like this

AI-powered drug discovery is changing the future of medicine

The pharmaceutical industry is being revolutionised by AI, transforming drug discovery with faster research and innovative treatments. Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, leveraging a novel clinical model for faster product development.

The Medicine of Tomorrow

Discover how groundbreaking research is revolutionising disease treatment at Monash Institute of Pharmaceutical Sciences. AI, biology, and data converge for life-changing advancements.

Hookipa Pharma advancing bold acquisition plans with Poolbeg Pharma

US-based biopharmaceutical innovator Hookipa Pharma is advancing non-binding discussions to acquire London-based Poolbeg Pharma in an all-share deal. This transformative proposal could reshape the clinical-stage biopharmaceutical landscape, creating a Nasdaq-listed powerhouse focused on next-generation immunotherapies for